ArticleApplied microbiology and biotechnology2025
A novel antibacterial approach: targeting methicillin-resistant Staphylococcus aureus with carvone nanoemulgel.
Article in Applied microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Molecular Targets and Biological Activities of Carvone: An Evidence-Graded Review.Molecules (Basel, Switzerland) · 2026Review
- Article
- Recent progress of plant-derived extracellular vesicle-like nanoparticles integrated with biomaterials for skin repair.Journal of nanobiotechnology · 2026Review
- Nanoemulgels as Advanced Topical Drug Delivery Systems: Mechanistic Insights and Therapeutic Applications in Skin Disorders, Infections, Wound Healing, and Cancer.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) remains a challenging issue in the treatment of diabetic wounds. The current researchinvestigates the formulation, antimicrobial, and wound healing efficacy of D-carvone-based nanoemulgel against clinical MRSA strains collected from diabetic wound infections. Nanoemulsion and nanoemulgel preparations for carvone were prepared and assessed. The antibacterial activity was assessed using both the cup method and microtiter assay, in addition to electron microscopy and molecular techniques. An excision wound model was used to evaluate the diabetic wound healing activity of NPs carvone. Diabetic rats, induced via streptozotocin (STZ, 65 mg/kg, i.p.), were separated into three groups: diabetic negative control, carvone, and NPs carvone groups, in which diabetic rats were allowed to heal spontaneously or treated by applying carvone alone or NPs carvone ointment, respectively. NPs D-carvone nanoemulgel demonstrated favorable characteristics suggesting enhanced tissue penetration; therefore, it was selected for further assessment. The antibacterial activity of D-carvone oil exhibited weak activity against all MRSA strains except for the AH-7 strain. On the other hand, both nanoemulsion and nanoemulgel formulations showed improved antibacterial effects, with the highest effect detected in strain AS-8 and the lowest in NCI-5, with MIC values ≤ 0.25 µg/ml for all strains. SEM images showed morphological changes in MRSA strains after treatment with NPs carvone. NPs carvone exhibited higher wound contraction %, faster epithelialization, and instigated collagen deposition, demonstrating enhanced healing processes. Additionally, NPs carvone intensified angiogenesis-related factors and antioxidant enzymes and reduced lipid peroxidation and inflammatory mediators. D-carvone nanoemulgel formulations exhibit effective antimicrobial activity against MRSA strains derived from diabetic wound infections. KEY POINTS: • D-carvone NP formulations exhibit effective antimicrobial activity against MRSA. • Nanoencapsulation improved efficacy and stability of D-carvone. • D-carvone nanoemulgels demonstrated superior diabetic wounds healing ability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.